Applied Clinical Trials Digital Edition - March 2012

Article

Applied Clinical Trials

Applied Clinical TrialsApplied Clinical Trials-03-01-2012
Volume 21
Issue 3

INFORMATION TECHNOLOGY : Revolution in Randomization Clinical Database: Proper Coding and Design Also in this issue : PDUFA Renewal, EFGCP Meeting on Informed Consent, Drug Development Cycle Time, Choosing an eClinical Solution

External Link - article-800708.pdf

Download Issue PDF
Articles in this issue
clintech-822583-1408532467458.jpeg
Re-Imagining CTMS
Applied Clinical Trials Digital Edition - March 2012
i1-764127-1408606715742.jpg
PDUFA Renewal Seeks Development Incentives
Biosimilar Guidances Issued
Increased eCRF Reuse Not Impacting Cycle Times?
Increased eCRF Reuse Not Impacting Cycle Times?
Site-Driven Metrics
i1-764124-1408606721902.jpg
Rethinking the Adage Time is Money
i1-764131-1408606703685.jpg
Alzheimer's Disease Presents Unique Problems in Volunteer Outreach and Retention
i1-764132-1408606699772.jpg
How Much Information for Informed Consent?
New Patient Group Targets DIA EuroMeeting
Subjects Share the Same Concerns
i4-764128-1408606712941.jpg
Randomization Revolution is Brewing
Leaping the Last Hurdle
i1-764121-1408606727951.jpg
Get the Business Right First
Grants Still Most Expensive in the United States
Grants Still Most Expensive in the United States

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!
Recent Videos
Related Content
Alexion’s Dual-Binding Nanobody Demonstrates Statistically Significant Improvements in Generalized Myasthenia Gravis

Alexion’s Dual-Binding Nanobody Demonstrates Statistically Significant Improvements in Generalized Myasthenia Gravis

Don Tracy, Associate Editor
July 25th 2025
Article

Results from the Phase III PREVAIL trial (NCT05556096) of gefurulimab demonstrated a statistically significant and clinically meaningful improvement in Myasthenia Gravis Activities of Daily Living at 26 weeks compared to placebo.

Unifying Industry to Better Understand GCP Guidance

Unifying Industry to Better Understand GCP Guidance

Andy Studna, Senior Editor
May 7th 2025
Podcast

In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.

Obefazimod Achieves Clinical Remission in Phase III Ulcerative Colitis Trials

Obefazimod Achieves Clinical Remission in Phase III Ulcerative Colitis Trials

Don Tracy, Associate Editor
July 24th 2025
Article

Results from the Phase III ABTECT-1 (NCT05507203) and ABTECT-2 (NCT05507216) trials showed that Abivax’s obefazimod demonstrated significant clinical remission in patients with ulcerative colitis.

Site Logo

Unlock Commercial Growth through Data-Driven Patient and HCP Insights Podcast

May 2nd 2025
Podcast
© JHVEPhoto - © JHVEPhoto - stock.adobe.com

FDA’s Elsa AI Tool Raises Accuracy and Oversight Concerns

Chris Mazzolini;Mike Hollan
July 23rd 2025
Article

Despite ambitions to streamline regulatory review, FDA’s Elsa platform has been prone to hallucinations, prompting internal scrutiny and questions about AI reliability and governance.

Report: Clinical Trial Searches Delay Treatment for Nearly 75% of Physicians

Report: Clinical Trial Searches Delay Treatment for Nearly 75% of Physicians

Don Tracy, Associate Editor
July 23rd 2025
Article

A new myTomorrows survey of physicians in the United States highlights the need for smarter, AI-driven tools to overcome inefficiencies in clinical trial access and improve patient care timelines.

© 2025 MJH Life Sciences

All rights reserved.